Add to My Stocks
Pharmerica Revenue Chart
$29.25 $0.05 (0.17%) PMC stock closing price Dec 07, 2017 (Closing)
The latest 2017-Q3 Pharmerica revenue is 595.1M. Compare Pharmerica revenue chart with China Cord Blood Corp revenue, LHC revenue.
PMC Revenue Chart
You can do annual as well as quarterly comparisons of PharMerica Corporation net sales with its competitor companies like China Cord Blood Corp, LHC. Over the 5 year period Pharmerica revenue in 2016 was highest at 2.09B. In the latest quarter, PMC revenue 2017-Q3 has changed from 592M to 595.1M implying an increase of 0.52%.
Pharmerica Quarterly Revenue
* Past 5 years Range
|Max PMC Revenue||$595.1M||Sep, 2017|
|Min PMC Revenue||$430.8M||Jun, 2013|
Pharmerica Annual Revenue
* Past 5 years Range
|Max PMC Revenue||$2.09B||Dec, 2016|
|Min PMC Revenue||$1.76B||Dec, 2013|
Pharmerica Annual Revenue VS Peers
|China Cord Blood Corp Revenue||$110.41M||$102.82M||$102.45M||$92.15M||$84.71M|
|Imprimis Pharma Revenue||----||$19.94M||$9.71M||$1.66M||$0.01M|
Pharmerica Stock Articles
Rowley Law PLLC is Investigating PharMerica Corporation and its Board of Directors for Potential Breaches of Fiduciary Duty
PharMerica (PMC) Alert: J&W Investigates Proposed Sale of PharMerica Corporation; Is $29.25 a Fair Price?
Revenue or net sales, also called topline or gross income is one of the most important financial metrics used to analyze a company. Revenue is the total amount of money that a company brings in through its various business activities, and appears as the ‘top line’ on the income statement. A company's net sales for a particular period can be found in its income statement. A healthy growth in revenue over time is generally considered good for the company, however other parameters such as profits must also be considered. We can calculate Pharmerica profits by subtracting expenses from Pharmerica revenue. Apart from analyzing a company's revenues over the years, it also helps to compare Pharmerica revenue with peers Almost Family topline, U.S. Physical Therapy topline, Omnicare topline; to see how the company is doing with respect to its peers.